Back to search

United Kingdom· GB-APID-41396311000001104

Epclusa 150mg/37.5mg granules sachets

A sofosbuvir and velpatasvir product containing sofosbuvir + velpatasvir, registered in United Kingdom by Gilead Sciences Ltd. The same ATC class is registered in 16 of our 19 countries.

ATC J05AP55

Checked against NHS dm+d (United Kingdom) on

Informational only — not a medical device.

SOURCE REGISTER · GBNHS dm+d (United Kingdom)normalisedEpclusa 150mg/37.5mg granules sachetsATCJ05AP55REGISTER NO.GB-APID-4139631100000…PACKS LISTED2CHECKEDSeptember 13, 2026

Where it is registered

Sofosbuvir and velpatasvir is registered in 16 of 19 countries.

Countries holding a registration under ATC J05AP55 (sofosbuvir and velpatasvir), each read from that country’s own register.

  • This record: United Kingdom, from NHS dm+d (United Kingdom)
  • 11 of them publish a price we can compare per daily dose

Sofosbuvir and velpatasvir · ATC J05AP55

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

NHS dm+d (United Kingdom)
Active substance
Sofosbuvir + Velpatasvir
Manufacturer
Gilead Sciences Ltd
Country
United Kingdom (GB)
ATC code
J05AP55
ATC class
Sofosbuvir and velpatasvir
Reimbursed
Not published by this register
Source register
NHS dm+d (United Kingdom)
Last checked
September 13, 2026

Packs & prices · 2

  • gtin
    05391507147363
  • gtin
    05391507147158

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

80 interactions on record for sofosbuvir and velpatasvir.

Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Sofosbuvir and velpatasvir · interactions on record

80 records

  • 14 severe
  • 61 moderate
  • 5 minor

Most severe, free to view

  • OmeprazoleA02BC01severe
  • PantoprazoleA02BC02severe
  • LansoprazoleA02BC03severe
  • RabeprazoleA02BC04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/839e53ea-c8e2-44b4-9ee7-5d6b34326433
GET /v1/drugs/839e53ea-c8e2-44b4-9ee7-5d6b34326433?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "apid": "41396311000001104",
  "desc": "Epclusa 150mg/37.5mg granules sachets (Gilead Sciences Ltd)",
  "form": "Oral granules",
  "vpid": "41411811000001105",
  "source": "dmd",
  "vtm_id": "777583008",
  "strength": "150 mg",
  "substance": "Sofosbuvir + Velpatasvir",
  "ingredient": "Sofosbuvir",
  "supplier_code": "2572301000001107"
}

See everything about sofosbuvir and velpatasvir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.